z-logo
open-access-imgOpen Access
Cost-Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Risk
Author(s) -
Suzanne J. Baron,
Kaijun Wang,
John A. House,
Elizabeth A. Magnuson,
Matthew R. Reynolds,
Raj Makkar,
Howard C. Herrmann,
Susheel Kodali,
Vinod H. Thourani,
Samir Kapadia,
Lars G. Svensson,
Michael J. Mack,
David L. Brown,
Mark J. Russo,
Craig R. Smith,
John G. Webb,
D. Craig Miller,
Martin B. Leon,
David J. Cohen
Publication year - 2019
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.118.035236
Subject(s) - medicine , valve replacement , stenosis , aortic valve replacement , aortic valve stenosis , cardiology , cost effectiveness , aortic valve , surgery , randomized controlled trial , risk analysis (engineering)
In patients with severe aortic stenosis (AS) at intermediate surgical risk, treatment with transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR) results in similar rates of death or stroke at 2 years. Whether TAVR is cost-effective compared with SAVR for intermediate-risk patients remains uncertain.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom